Research and Markets (http://www.researchandmarkets.com/research/5f272c/biotherapy_market) has announced the addition of the "Biotherapy Market Study" report to their offering.
“the use of substances from a living organism or living organism itself, such as a leech, in treating people or animals.”
"Following its recent successful integration into mainstream medicine, biotherapy will continue to grow since it offers potent, natural and cost-effective treatments to both people and animals," Dr. David Kaplun, Manager and Founder, ICB (International Center for Biotherapy).
The outline purpose of this market study was to research the biotherapy market in general, focusing on treatments with maggots and leeches.
NEED FOR BIOTHERAPY
In the context of this study, biotherapy was defined as "the use of substances from a living organism or living organism itself, such as a leech, in treating people or animals."
The revival of biotherapy is fuelled by market drivers, including: Modern medicine is limited since current medications deal more with symptoms than anything else; many medical uses of biotherapy (e.g. those of leeches); biotherapy is cost-effective; failure of substitutes (e.g. the failure of the mechanical leech); healing wounds with biotherapy; and helping with the symptoms of arthritis.
BIOTHERAPY MARKET
The CAM (Complementary and Alternative Medicine) market, of which the biotherapy market is a part of, has witnessed accelerated growth.
MDT (Maggot Debridement Therapy) has also grown. In 1995, only a few doctors in 4 countries were using MDT. Today, any U.S. physician can prescribe MDT. Over 4,000 therapists are using MDT in 20 countries.
Leech therapy has also grown. For example, at Biopharm, an international supplier of leeches, annual sales have doubled to more than 70,000 of the animals in the previous 15 years. The two main commercial weaknesses of leech therapy are the "yuck" factor and the lack of randomized clinical trials.
METHODOLOGY